Delivery of Biologics for Angiogenesis and Myogenesis

Law, Peter K.; Chin, S.; Hung, Huynh Duong; Nguyen, Thach; Feng, Quan–Zhou

doi:10.1002/9781444312584.ch30

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lotreleasetesting consisted of sterility, endotoxin, mycoplasma, and testing for myoblast identity, purity, potency, viability, and cell count on a pooled sample prior to transplant meeting quality control standards [13] [14] [15]. A retain sample of myoblasts was reserved from each transplant.…”

Section: Manufacture Of Allogeneic Human Myoblastsmentioning

confidence: 99%

Two-Year Heart Failure Study with Allogeneic Myoblast Transplantation

Li¹,

Wang²,

Shi³

et al. 2021

OJRM

Self Cite

View full text Add to dashboard Cite

Objectives: Allogeneic myoblast transplantation (AMT), cyclosporine immunosuppression and coronary artery bypass grafting (CABG) were used to treat end-stage heart failure (HF) subjects without hope of obtaining a heart transplant. Background: Severe myocardial infarction conveys serious complications such as ventricular aneurysm, wall thinning and rupture with fatal consequences. Methods: After meeting Inclusion/Exclusion criteria and signing Patient Informed Consents, 10 HF subjects having mean thinnest wall thickness of 2.21 ± 0.55 mm and ventricular aneurysms were admitted under intensive care. Each subject took daily cyclosporine for three weeks. On the third day of cyclosporine administration, approximately 1 billion myoblasts were implanted through 20 injections into the infarcted myocardium following CABG. Results: Safety No subject suffered death, viral infection, malignant arrhythmia, reduction in cardiac output, immune rejection, or aneurysm growth. No significant difference was found before versus after treatment in the mean levels of blood routine, liver and kidney enzymes, electrolytes and fibrinogen. Efficacy Emission computed tomography (ECT) and magnetic resonance (MR) demonstrated significant increases in viability and perfusion. Mean left ventricular ejection fraction (LVEF) significantly increased (P < 0.05) by 20.1% and 19.3% at 6 months and at 2 years postoperatively. New York Heart Association (NYHA) class improved by 2 grades, including 6-minute walk test (6 MWT) distance increase, and reductions in the number of episodes of angina pectoris, chest tightness, shortness of breath after exercise, and nighttime sit-up breathing. Conclusions: For the first time, AMT in adjunct use with CABG and cyclosporine demonstrated that cell survived and engrafted in patients with ischemic cardiomyopathy; in this small study the cell transplant

show abstract

Section: Manufacture Of Allogeneic Human Myoblastsmentioning

confidence: 99%

Two-Year Heart Failure Study with Allogeneic Myoblast Transplantation

Li¹,

Wang²,

Shi³

et al. 2021

OJRM

Self Cite

View full text Add to dashboard Cite

show abstract

“…The LV can only be pierced by the needle a maximum of 20 times before the possible induction of heart arrhythmia. Therefore, in a procedure with 20 injections, each injection should emit 0.5 ml of 10 8 cells/ml myoblast solution 21,22 .…”

Section: Design Scopementioning

confidence: 99%

Conceptual Design and Procedure for an Autonomous Intramyocardial Injection Catheter

Cheng

Law

2017

Cell Transplant

Self Cite

View full text Add to dashboard Cite

This article discusses existing catheter systems and proposes a conceptual design and procedure for an autonomous cell injection catheter for the purpose of transferring committed myogenic or undifferentiated stem cells into the infarct boundary zones of the left ventricle. Operation of existing catheters used for cell delivery is far from optimal. Commercial injection catheters available are handheld devices operated manually by means of tip deflection and torque capabilities. Interventionists require a hefty learning curve and often encounter difficulties in catheter stabilization and infarct detection, resulting in lengthy operation times and nonprecise injections. We examined current technologies and proposed a design incorporating robotic positional control, feedback signals, and an adaptable operational sequence to overcome these problems. The design provides the basis for robotic catheter construction that is able to autonomously assist the physician in transferring myogenic cells to the left ventricle infarct boundary zones.

show abstract

“…The purpose of the design is to optimize the catheter procedure for the injection of myogenic or undifferentiated stem cells into the infarct boundary zones of the left ventricle (LV). Previous studies [28][29][30] have shown that the optimal method in cell delivery would be injecting the needle into an infarct boundary zone at a diagonal angle while the needle is retracting. As difficulties occur in locating and maintaining the catheter tip at the target infarct boundary zones during such an injection, a remotely controlled catheter with finer positioning capabilities may be necessary.…”

Section: Conceptual Designmentioning

confidence: 99%

Feedforward Coordinate Control of a Robotic Cell Injection Catheter

Cheng

Law

2017

Cell Transplant

Self Cite

View full text Add to dashboard Cite

Remote and robotically actuated catheters are the stepping-stones toward autonomous catheters, where complex intravascular procedures may be performed with minimal intervention from a physician. This article proposes a concept for the positional, feedforward control of a robotically actuated cell injection catheter used for the injection of myogenic or undifferentiated stem cells into the myocardial infarct boundary zones of the left ventricle. The prototype for the catheter system was built upon a needle-based catheter with a single degree of deflection, a 3-D printed handle combined with actuators, and the Arduino microcontroller platform. A bench setup was used to mimic a left ventricle catheter procedure starting from the femoral artery. Using Matlab and the open-source video modeling tool Tracker, the planar coordinates (y, z) of the catheter position were analyzed, and a feedforward control system was developed based on empirical models. Using the Student’s t test with a sample size of 26, it was determined that for both the y- and z-axes, the mean discrepancy between the calibrated and theoretical coordinate values had no significant difference compared to the hypothetical value of µ = 0. The root mean square error of the calibrated coordinates also showed an 88% improvement in the z-axis and 31% improvement in the y-axis compared to the unmodified trial run. This proof of concept investigation leads to the possibility of further developing a feedfoward control system in vivo using catheters with omnidirectional deflection. Feedforward positional control allows for more flexibility in the design of an automated catheter system where problems such as systemic time delay may be a hindrance in instances requiring an immediate reaction.

show abstract

Delivery of Biologics for Angiogenesis and Myogenesis

Cited by 3 publications

References 0 publications

Two-Year Heart Failure Study with Allogeneic Myoblast Transplantation

Two-Year Heart Failure Study with Allogeneic Myoblast Transplantation

Conceptual Design and Procedure for an Autonomous Intramyocardial Injection Catheter

Feedforward Coordinate Control of a Robotic Cell Injection Catheter

Contact Info

Product

Resources

About